Shenzhen Hepalink Pharmaceutical Group (9989) Stock Overview
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
9989 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.31 |
| 52 Week High | CN¥7.26 |
| 52 Week Low | CN¥3.60 |
| Beta | 0.50 |
| 1 Month Change | 3.71% |
| 3 Month Change | 1.53% |
| 1 Year Change | 42.36% |
| 3 Year Change | -7.49% |
| 5 Year Change | -56.90% |
| Change since IPO | -69.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9989 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -0.6% | 4.8% | 1.6% |
| 1Y | 42.4% | 91.0% | 36.3% |
Return vs Industry: 9989 underperformed the Hong Kong Pharmaceuticals industry which returned 91% over the past year.
Return vs Market: 9989 exceeded the Hong Kong Market which returned 36.3% over the past year.
Price Volatility
| 9989 volatility | |
|---|---|
| 9989 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 2.9% |
Stable Share Price: 9989 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9989's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,926 | Yu Shan | www.hepalink.com |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 9989 fundamental statistics | |
|---|---|
| Market cap | HK$18.33b |
| Earnings (TTM) | HK$470.13m |
| Revenue (TTM) | HK$6.02b |
Is 9989 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9989 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.38b |
| Cost of Revenue | CN¥3.67b |
| Gross Profit | CN¥1.71b |
| Other Expenses | CN¥1.29b |
| Earnings | CN¥420.20m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 31, 2026
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 31.77% |
| Net Profit Margin | 7.80% |
| Debt/Equity Ratio | 24.5% |
How did 9989 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 16:55 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Yinglan Shu | Haitong International Research Limited |
| Laurence Tam | Morgan Stanley |